Welcome to our dedicated page for CG Oncology SEC filings (Ticker: CGON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CG Oncology, Inc. (NASDAQ: CGON) SEC filings page provides access to the company’s official U.S. Securities and Exchange Commission disclosures related to its late-stage clinical biopharmaceutical activities in non-muscle invasive bladder cancer (NMIBC). As a public company, CG Oncology files periodic and current reports that describe its financial condition, governance changes, and key clinical and regulatory milestones for its investigational intravesical oncolytic immunotherapy, cretostimogene grenadenorepvec.
Among the most relevant documents for CGON are current reports on Form 8-K, which the company uses to report material events. Recent 8-K filings have detailed board of director changes, including the appointment of a new director and the resignation of another, as well as transitions in the principal financial and accounting officer role. Other 8-Ks reference press releases announcing quarterly financial results, updated BOND-003 Cohort C data in high-risk BCG-unresponsive NMIBC, and corporate presentations at healthcare conferences.
Investors also look to CG Oncology’s quarterly and annual reports (Forms 10-Q and 10-K, when available) for broader context on its clinical development program, including the BOND-003 and PIVOT-006 Phase 3 trials and the CORE-008 Phase 2 study, as well as information about its Expanded Access Program in North America. These filings typically discuss risk factors, research and development expenses, and other elements that shape the company’s outlook as a late-stage clinical biopharmaceutical issuer.
On Stock Titan, CGON filings are updated as they are posted to EDGAR, and AI-powered tools can help summarize lengthy documents such as earnings-related 8-K exhibits or future 10-K and 10-Q reports. Users can also review governance and compensation disclosures embedded in 8-K items related to director appointments and executive transitions, and track how these developments align with CG Oncology’s efforts to advance cretostimogene through the regulatory process.